• Sirolimus monotherapy is a safe and effective, steroid-sparing agent, improving autoimmune cytopenias in highly refractory patients.
and CASP10 (2-3%) 9, 10 . Approximately one-third of patients with ALPS have yet undetermined genetic defects, ALPS-U
11
.
Treatment of patients with ALPS varies significantly, with no consensus on the management.
We have previously demonstrated that treatment with the mTOR inhibitor, sirolimus (rapamycin, Rapamune) led to a complete response (CR) in a small retrospective cohort of 5 children with corticosteroid refractory autoimmune lymphoproliferative syndrome (ALPS) 5 . Based on that study, we opened a prospective multi-institutional clinical trial (NCT00392951) using sirolimus for children with treatment-refractory ALPS. After we found an early efficacy signal, we broadened the inclusion criteria to any child with autoimmune cytopenias who failed or was intolerant to standard immunosuppressive therapy (corticosteroids and/or intravenous immunoglobulin G (IVIgG)). We report the results of 30 patients treated on the trial and found that sirolimus is well tolerated for both short and long-term use. The majority of the patients had a complete and durable response with few to no adverse effects. We also monitored immune function on a subset of the patients and found sirolimus was effective and did not suppress B or
T cell numbers or function in the majority of patients with secondary autoimmune cytopenias.
We would propose that sirolimus should be considered as a first-or second-line agent in certain patients with chronic and refractory autoimmune cytopenias.
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MATERIALS and METHODS

Patients
Patients aged >= 12 months to < 40 years of age, with a diagnosis of autoimmune cytopenias requiring medications, were eligible. "Autoimmune" was defined by meeting one of the following criteria: documented autoantibody (positive direct antiglobulin test (DAT), antineutrophil or anti-platelet antibody), or a history of documented clinical response to immunosuppression. Patients must have at least one of the following: autoimmune neutropenia, autoimmune thrombocytopenia, or autoimmune hemolytic anemia. The diagnosis of ALPS was made based on revised criteria 11 .
Study Design
This was a multi-center, prospective, open label clinical trial to evaluate the safety and efficacy of sirolimus in children and young adults with autoimmune cytopenias who are either refractory to standard therapy or have significant toxicity from standard treatments. (Clinicaltrials.gov ID: NCT00392951). A total of 15 different treating institutions from across the United States were included in this study. As autoimmune cytopenias are rare, subjects traveled to the Children's Hospital of Philadelphia or Children's Hospital of Wisconsin for consent, but all study procedures including prescription of sirolimus, lab monitoring, and physical exams occurred at the referring primary institutions. All patients on the study gave written informed consent. The study was approved by local institutional review boards (IRB), and was conducted in accordance with the provision of the Declaration of Helsinki and Good Clinical Practice guidelines.
Treatment
Sirolimus was given at a dose of 2-2.5 mg/m 2 /day rounded to the nearest 0.5 (liquid) or 1 mg (tablet), starting on day 1 (maximum initial dose of 4 mg/day). Detailed description regarding the recommended dose adjustment is included in the supplemental methods. The anticipated length of treatment with sirolimus was six months, however patients with a favorable response were given the option to continue treatment with continued serial follow-up to monitor for efficacy and toxicity.
Evaluation of disease responses and toxicity monitoring
The response criteria for autoimmune cytopenia, lymphadenopathy and splenomegaly are included in Supplemental Table S1 . Evaluation of response was monitored by blood counts measured every two weeks until trough sirolimus goal levels were reached, then spaced to every three months. As additional measures of efficacy, immune cell assays and measures of immune function were performed in a portion of patients, including T cell subsets (CD4 + , CD8 + , and DNTs), quantitative IgG, and mitogen assays, including phytohemagglutinin A (PHA), concanavalin A (con A) and poke weed mitogen (PWM). All patients underwent periodic biochemical analysis in order to evaluate organ toxicity. All adverse events (AEs) were assessed at each patient visit and were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (version 4.0). Assessments of efficacy and safety were conducted formally every 3 months, and followed long-term.
Statistical analysis
Descriptive statistics were reported in terms of absolute frequencies and percentage for qualitative data. Distribution of data regarding continuous variables was described in terms of a 
RESULTS
Patient Characteristics
A total of 30 patients (20 males, 10 females) with autoimmune cytopenias intolerant to or having failed other therapies, including corticosteroids, mycophenolate mofetil (MMF), IVIgG and rituximab, were included and treated with sirolimus (Table S2) . Underlying diagnosis and type of cytopenia and/or organomegaly, and demographic information are shown in Tables 1 and 2 (divided by ALPS vs. non-ALPS diagnoses). Of the 30 patients, 12 were diagnosed with ALPS (6 with constitutional FAS (ALPS-FAS) mutations, 3 with somatic FAS mutations (ALPS-sFAS) and 3 undetermined (ALPS-U)), 8 with Evans syndrome, 2 with common variable immunodeficiency (CVID), 2 with systemic lupus erythematosus (SLE), and 6 with single lineage cytopenias, including immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) ( Table 1 ). The median age of all patients at the time of diagnosis was 5 years (range 5 months to 19 years) and at the start of sirolimus was 11 years (range 1.8 to 21 years).
The main indications for sirolimus treatment in all subjects were steroid intolerance and/or inability to wean off steroids or other immunosuppressants (Tables 1 and 2 ). All of the patients diagnosed with ALPS were previously treated with corticosteroids. Nine of the 12 patients demonstrated a response to steroids but were unable to maintain the response with weans. The remaining 3 had either a poor or no response to steroids. Other immunosuppressant agents previously trialed included MMF, rituximab, and IVIgG prior to the start of sirolimus (Table 1 ).
Seven of the 9 patients had no response to IVIgG, 1 of 9 had a transient response but would relapse quickly, while 1 had an improvement only in thrombocytopenia. MMF was trialed in 7 of the 12: 3 had no response, while the remainder had only a partial response with a mild (GCSF), divalproex sodium (depakote), methotrexate and mercaptopurine (6-MP). In spite of some anecdotal evidence for these drugs in refractory ALPS, the subjects treated with these drugs prior to sirolimus had no response.
Subjects with multi-and single-lineage cytopenias with or without lymphoproliferative disease not diagnosed with ALPS were similarly trialed with several immunomodulating agents including steroids, MMF, IVIgG and rituximab (Table 2) . Steroids were most successful in leading to a response in 9 of 18 subjects; however as was seen in ALPS subjects, steroids were unable to be weaned. Eleven of 16 subjects treated with IVIgG had no response, poor in 4 subjects, and only one transiently responded to IVIgG. The response to rituximab was somewhat better, with a CR in 6 of 12, 1 allergic reaction, 5 NR. The CRs however were all short-lived.
Three subjects relapsed in less than 6 months and the other three prior to 1 year. The responses to MMF however were very poor, resulting in an NR (N= 5 of 7) or a PR (N= 2 of 7) (Table S3 ).
Pharmacokinetics
After the start of sirolimus, drug troughs were monitored twice weekly until they reached a steady state. All of the patients with ALPS achieved a goal trough level by the first measurement, ranging between 4.6 to 20 ng/mL. Of the other subjects, four achieved a suboptimal trough level, range 2.9 -4.6ng/mL, and the remaining patients' first trough levels ranged between 5.2 to 13.9ng/mL. In all subjects, only 1-3 dose adjustments were necessary, and were made in an effort to achieve more optimal cytopenia responses. Even with these adjustments, the target serum levels were maintained and did not exceed 15ng/mL.
Efficacy
In subjects with ALPS, 11 of 12 experienced a hematologic CR within 3-months of starting sirolimus (Figures 1 and 2 ; further support these findings, additional patients diagnosed with ALPS and treated with sirolimus on a clinical basis were monitored through enrollment on a parallel biology study ( Figure 3B ). Seven of these subjects also had pre-and post-sirolimus measurement of DNTs, with similar improvements. Of the 7 subjects, four had resolution in the DNT% <=2.6% of CD3+ cells. While not all of the patients had DNT <2.6%, their percent change was just as robust, ranging between 40.8 to 90.2% change, which was statistically significant, P=.0156. As additional validation of the downward trend in DNT percentage after starting sirolimus, absolute DNTs (%DNTs x absolute lymphocyte count) were also provided, Supplemental Figure S1 , demonstrating an almost superimposable trend.
Most of the non-ALPS subjects with multi-lineage autoimmune cytopenias also responded to sirolimus ( 
( Figure 2A ). One subject stopped sirolimus for toxicity (see "Toxicity / Safety"). Two of the patients with multi-lineage cytopenias achieved a PR. The remaining 2 of 12 were nonresponders. Importantly, subjects who achieved a CR after starting sirolimus were weaned off other medications within 2 weeks to 1 month.
The responses in patients with single lineage autoimmune cytopenias were less robust ( Figure   2A and 4). Four children with ITP were treated, of which 3 did not respond, and 1 subject had a PR that lasted approximately 6 months before therapy was stopped. Two children with AIHA were treated. One had a CR by 6 months on therapy and was able to wean off other medications within a month. Of note, this patient has a mutation in CASP10, an ALPS-associated gene;
however, this subject did not meet the diagnostic criteria for ALPS, as DNTs were not elevated at baseline. The other child with AIHA achieved a PR; although this patient had a complete resolution of cytopenias when compliant with sirolimus, likely reflecting adequate serum levels;
when the subject discontinued sirolimus (which happened often), his disease would flare.
Many of the patients that achieved a CR have been continued on sirolimus with durable responses ( Figure 2B and 2C). Follow-up of all patients ranged from 0 to 8 years, with a median of 2 years. All of the ALPS patients experienced durable responses and chose to remain on sirolimus beyond the study goal of 6 months (median 3.5 years, range 1.5-8 years). Further, those patients that achieved a CR were able to wean off all corticosteroids. Only 1 ALPS patient chose to discontinue sirolimus and has not had any exacerbation of the underlying cytopenias.
Of the non-ALPS patients, the length of time on sirolimus was shorter, ranging between 1 to 4.5 years ( Figure 2B and 2C). Not surprisingly, the subjects with multi-lineage disease (i.e. Evans, CVID or SLE) were more likely to remain on study, while only one subject with single lineage disease remained on sirolimus up to 1 year, after achieving a CR. The remainder came off study between 2 to 6 months mostly due to non-response. Of note, the shorter follow-up time partly reflects the timing of the study not open to non-ALPS subjects for the first 2 years.
Toxicity / Safety
Overall, sirolimus was well tolerated with few side effects. The presence and/or the severity of toxicity did not correlate with trough levels or likelihood to achieve a CR. The most common adverse effect of sirolimus was grade 1-2 mucositis (N=10 of 30). This occurred most often within the first 3 months of initiating sirolimus and resolved without therapy modification.
Other toxicities included elevated triglycerides and elevated cholesterol (n=2), that responded to fish oil or atorvastatin. One patient developed hypertension two years after starting sirolimus, although this was temporally related to starting a new psychiatric medication. Other side effects included acne (N=1), sun sensitivity (N=1), and exacerbation of gastro-esophageal reflux disease (N=1). One subject with Evans achieved a PR after 3-months however later developed a headache with associated white matter changes (4 different lesions) noted by brain MRI. These changes were not consistent with posterior reversible encephalopathy syndrome (PRES) or posterior multifocal leukoencephalopathy (PML). An extensive workup was negative for an infectious etiology including JC polyomavirus or demyelination. Sirolimus was discontinued and the headaches resolved within a few days. This subject successfully reached normal blood counts on sirolimus and weaned off all other immune suppressive medications. Nevertheless
based on toxicity, the sirolimus was discontinued prior to determining if the patient could maintain normal counts for 2 months, and this patient was classified as having a PR. The changes were eventually attributed to disease-associated vasculitis, and the lesions noted on MRI resolved over the next few months with the addition of steroids. This patient was eventually diagnosed with a primary T cell immune deficiency and underwent hematopoietic stem cell transplant.
Immune function
Sirolimus is most commonly used to suppress the immune system and prevent rejection after solid organ transplant. Often sirolimus is used in combination with other immunosuppressive drugs making it challenging to understand the risk for infection noted in the literature associated with these drugs 13 . Therefore, we wanted to ensure that sirolimus monotherapy did not impair the function of normal immune cells.
Quantitative and qualitative assessments of immune function were obtained in a subset of patients ( Figure 5 and 6). Overall, ALPS patients treated with sirolimus did not have a reduction in B or T cell number or function, as assessed absolute lymphocyte counts (ALC), quantitative IgG, CD4, and CD8 counts, or mitogen stimulation after over one year on therapy ( Figure 5 ).
Immune function was also measured in 12 subjects with multi-lineage cytopenias without the diagnosis of ALPS, between 3-months to 4 years after the start of sirolimus ( Figure 6 ). Unlike the patients with ALPS, the responses were more heterogeneous: some patients had reductions in B and T cell number and function, while others did not. 
third-line treatment, of which 75% responded; while 67% of those patients had previously failed MMF. Of note, however, no ALPS patients received sirolimus in that study.
This is the first prospective multi-center clinical trial evaluating the safety and efficacy of sirolimus for patients with refractory autoimmune multi-lineage cytopenias. We found that sirolimus is a safe and effective, steroid-sparing monotherapy for refractory autoimmune cytopenias. Sirolimus not only leads to improvements in cytopenias, it also leads to improvement in lymphoproliferation, as the enlarged LNs and spleen shrink significantly with reduction of the signature DNT cell numbers. In patients with ALPS, they all achieved a CR for both autoimmune cytopenias and manifestations of lymphoproliferative disease. Further, DNTs in the ALPS subjects dropped to a normal range, <= 2.6%. We have also guided clinicians in the treatment of over 30 additional children with ALPS from 18 different countries on 6 continents, with sirolimus. As these are anecdotal, we cannot report efficacy or safety data, however can report that sirolimus is a feasible option for children worldwide.
Based on the results seen in patients with ALPS, we also treated patients with non-ALPS autoimmune cytopenias. In these patients with multi-lineage autoimmune cytopenias, including
Evans, CVID and SLE, there was a similar dramatic response to sirolimus noted with a CR in 67% (8/12). Only 6 of 12 non-ALPS patients (with multi-lineage cytopenias) manifested lymphoproliferative disease including mild to moderate lymphadenopathy and/or splenomegaly, with the majority (67%, 4/6), having achieved a CR in lymphoproliferation, one patient with a PR (17%, 1/6), and one patient was a non-responder (16%, 1/6). The funding sources had no role in data collection, analysis, or interpretation of the data, the writing of the report, or the decision to submit for publication. 
• CR** • CR**
• CR** • CR** 4.5 yrs ALPS-FAS A+N+T Massive LAD splenomegaly
• CR** • CR** 2 yrs
1.5 yrs ALPS-sFAS A+N+T Massive LAD and splenomegaly
4.5 yrs ALPS-sFAS A+N+T Mild LAD and splenomegaly
ALPS-sFAS A+N+T Massive LAD and
A+N+T Massive LAD and splenomegaly
ALPS-U A+N+T Massive LAD and splenomegaly
3 yrs * For simplicity, the first bulleted row refers to the heme response, while the second bulleted row refers to the lymphadenopathy and splenomegaly ** Designate the patients who remain in a durable CR but have occasional, mild, transient disease flares manifested as dropping blood counts or the development of lymphadenopathy with viral illness. These "flares" are mild and do not require the use of additional immune suppression, as they self-resolve following the resolution of the infection. 
Off study Off study 5 months
• NR Off study Off study N/A Evans A+N+T Mild LAD and splenomegaly
• NR Off study Off study
• Splenectomy NR Off study Off study 1 month
Off study 6 months
• NR Off study Off study 2 months
• NR Off study Off study 3 months
Intermittent 4 years AIHA A Marked LAD and splenomegaly Overall time to achieve a CR on sirolimus, in patients with ALPS compared to non-ALPS patients separated by multi-lineage vs. single-lineage autoimmune cytopenias. For patients whose best response was PR or NR, the curve represents time on sirolimus plus one year of observation after discontinuation. The time to CR was not significantly different in ALPS (median 4 weeks, range 2 -60) compared to non-ALPS patients with multi-lineage cytopenias (median 9 weeks, range 2 -260), P=.135. In contrast, the time to CR was significantly different in ALPS compared to non-ALPS patients with single-lineage cytopenias P=.0065. * One patient with non-ALPS single lineage disease achieved a PR and remained on drug for 260 weeks. (B) Relapse incidence in ALPS and non-ALPS patients with multi-lineage and single-lineage cytopenias, for all patients enrolled. Events include patients who achieved a CR and then relapsed, and patients who discontinued sirolimus for lack of efficacy. Most of the ALPS patients remained disease-free while on sirolimus, including one patient who stopped sirolimus after 3 years but maintained a durable CR. The median time to an event in non-ALPS patients is 13 months. Of note, 2 non-ALPS patients with multi-lineage cytopenias electively stopped sirolimus, had a transient drop in counts, and then were re-challenged with sirolimus, reverting back to a CR. These patients were not counted as having relapsed. (C) Histogram demonstrating the total time on sirolimus separated by ALPS, non-ALPS multi-lineage vs. non-ALPS-single lineage. The different colors reflect whether they achieved a CR, (black), PR (gray), or NR (white). diagnosed with comorbid CVID prior to starting sirolimus. Interestingly, the other subject with hypogammaglobulinemia developed it while on chronic MMF, requiring chronic IVIgG replacement for many years. After starting sirolimus, the hypogammaglobulinemia improved. The child was subsequently challenged with vaccines and demonstrated normal antibody response and was able to discontinue IVIgG supplementation. (C) CD4 and (D) CD8 counts were also studied in 5 ALPS patients pre-and post-long-term administration of sirolimus, with no decrease in number, P=.1875, P=.3125 respectively. Not depicted here, however 5 ALPS patients had mitogen stimulation measured between 2 and 5 years after initiation of sirolimus, with robust responses to PHA, con A and PWM. Measurements post-sirolimus treatment varied per subject, between 1 to 5 years of treatment. subjects demonstrated an increase in the ALC, 2 with no change, 2 with decreases but remained normal, and 3 subjects whose ALC dropped to a more moderate lymphopenia range (postsirolimus ALC range 320-3456/ L; P >.999). (B) IgG quantification; for most remained in a normal range, and were unchanged before and after the use of sirolimus (P=.8438) (C) CD4 and (D) CD8 counts were monitored pre-and post-long-term administration of sirolimus. CD4 and CD8 counts mostly either remained the same or increased (P=.8438, P=.6250 respectively). Three subjects had a decrease in the CD4 count, however only 1 fell to a level < 200/ L. That same patient also demonstrated a drop in CD8 count to a low level (from 492 to 96/ L), after 3-months of sirolimus. Also not depicted here, the response to mitogens was available on 3 subjects: one remained normal at 1 year, while 2 were reduced at 1 and 4 years. Measurements post-sirolimus treatment varied per subject, between 3-months to 4 years of treatment.
